Moreover, beyond their efficacy in treating diabetic kidney disease, it is now established that SGLT2 inhibitors do not elevate the risk of AKI, providing reassurance regarding their safety profile in this aspect (Sridhar et al., 2020). Here, SLC5A2 is linked to diabetic kidney disease.